Burden of disease in multiple sclerosis patients with spasticity in Germany: Mobility improvement study (Move I)

European Journal of Health Economics

Volumn 15, Issue 9, 2014, Pages 953-966

  Zettl, Uwe K ^a   Henze, Thomas ^b   Essner, Ute ^c   Flachenecker, Peter ^d  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Passauer Wolf Rehabilitation Center Nittenau   (Germany)

^c Almirall Hermal   (Germany)

^d Neurological Rehabilitation Center Quellenhof   (Germany)

Author keywords

Burden of disease; Cost; Multiple sclerosis; Quality of life; Spasticity

Indexed keywords

EID: 84888252468     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-013-0537-5     Document Type: Article

References (76)

1. Millar, J.H.: Multiple sclerosis. Br. Med. J. 280, 184–185 (1980)
2. Nicholas, R., Rashid, W.: Multiple sclerosis. Clin. Evid. pii: 1202 (2012). Accessed 10 Feb 2012
3. McDonald, I., Compston, A.: The symptoms and signs of multiple scleroses. In: Compston, A., Ebers, G., Lassmann, H., McDonald, I., Matthews, W.B., Wekerle, H. (eds.) McAlpine’s multiple sclerosis, 4th edn. Elsevier, Philadelphia (2006)
4. Antel, J., Antel, S., Caramanos, Z., Arnold, D.L., Kuhlmann, T.: Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol. 123, 627–638 (2012)
5. Loma, I., Heyman, R.: Multiple sclerosis: pathogenesis and treatment. Curr. Neuropharmacol. 9, 409–416 (2011)
6. Weinshenker, B.G.: Natural history of multiple sclerosis. Ann. Neurol. 36(Suppl), 6–11 (1994)
7. Tsang, B.K.: Macdonell. Multiple sclerosis- diagnosis, management and prognosis. Aust. Fam. Physician. 40, 948–955 (2011)
8. Murray, T.J.: Diagnosis and treatment of multiple sclerosis. BMJ 332, 525–527 (2006)
9. Harper, A.C., Harper, D.A., Chambers, L.W., Cino, P.M., Singer, J.: An epidemiological description of physical, social and psychological problems in multiple sclerosis. J. Chronic Dis. 39, 305–310 (1986)
10. Lankhorst, G.J., Jelles, F., Smits, R.C., Polman, C.H., Kuik, D.J., Pfennings, L.E., Cohen, L., van der Ploeg, H.M., Ketelaer, P., Vleugels, L.: Quality of life in multiple sclerosis: the disability and impact profile (DIP). J. Neurol. 243, 469–474 (1996)
11. Rudick, R.A., Miller, D., Clough, J.D., Gragg, L.A., Farmer, R.G.: Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch. Neurol. 49, 1237–1242 (1992)
12. Rao, S.M., Leo, G.J., Ellington, L., Nauertz, T., Bernardin, L., Unverzagt, F.: Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 41, 692–696 (1991)
13. Rizzo, M.A., Hadjimichael, O.C., Preiningerova, J., Vollmer, T.L.: Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 10, 589–595 (2004)
14. Beard, S., Hunn, A., Wight, J.: Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol. Assess. 7, 1–111 (2003)
15. Barnes, M.P., Kent, R.M., Semlyen, J.K., McMullen, K.M.: Spasticity in multiple sclerosis. Neurorehabil. Neural. Repair. 17, 66–70 (2003)
16. Lance, J.W.: The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology. 30, 1303–1313 (1980)
17. Zwibel, H.L.: Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv. Ther. 26, 1043–1057 (2009)
18. Cameron, M.H., Wagner, J.M.: Gait abnormalities in multiple sclerosis: pathogenesis, evaluation, and advances in treatment. Curr. Neurol. Neurosci. Rep. 11, 507–515 (2011)
19. Crayton, H.J., Rossman, H.S.: Managing the symptoms of multiple sclerosis: a multimodal approach. Clin. Ther. 28, 445–460 (2006)
20. Hobart, J.C., Riazi, A., Thompson, A.J., Styles, I.M., Ingram, W., Vickery, P.J., Warner, M., Fox, P.J., Zajicek, J.P.: Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 129, 224–234 (2006)
21. Zwibel, H.L., Smrtka, J.: Improving quality of life in multiple sclerosis: an unmet need. Am. J. Manag. Care. 17(Suppl 5), 139–145 (2011)
22. Souza, A., Kelleher, A., Cooper, R., Cooper, R.A., Iezzoni, L.I., Collins, D.M.: Multiple sclerosis and mobility-related assistive technology: systematic review of literature. J. Rehabil. Res. Dev. 47, 213–223 (2010)
23. Henze, T., Rieckmann, P., Toyka, K.V.: Symptomatic treatment of multiple sclerosis. Eur. Neurol. 56, 78–105 (2006)
24. Rekand, T., Grønning, M.: Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J. Rehabil. Med. 43, 511–514 (2011)
25. Ben Smail, D., Peskine, A., Roche, N., Mailhan, L., Thiébaut, I., Bussel, B.: Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult. Scler. 12, 101–103 (2006)
26. Penn, R.D., Savoy, S.M., Corcos, D., Latash, M., Gottlieb, G., Parke, B., Kroin, J.S.: Intrathecal baclofen for severe spinal spasticity. N. Engl. J. Med. 320, 1517–1521 (1989)
27. Sachais, B.A., Logue, J.N., Carey, M.S.: Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch. Neurol. 34, 22–28 (1977)
28. Hudgson, P., Weightman, D.: Baclofen in the treatment of spasticity. Br. Med. J. 4, 15–17 (1971)
29. Groves, L., Shellenberger, M.K., Davis, C.S.: Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv. Ther. 15, 241–251 (1998)
30. Lapierre, Y., Bouchard, S., Tansey, C., Gendron, D., Barkas, W.J., Francis, G.S.: Treatment of spasticity with tizanidine in multiple sclerosis. Can. J. Neurol. Sci. 14, 513–551 (1987)
31. Kabus, C., Hecht, M., Japp, G., Jost, W.H., Pöhlau, D., Stuckrad-Barre, S., Winterholler, M.: Botulinum toxin in patients with multiple sclerosis. J. Neurol. 253, i26–i28 (2006)
32. Smyth, M.D., Peacock, W.J.: The surgical treatment of spasticity. Muscle Nerve 23, 153–163 (2000)
33. Arroyo, R., Vila, C., Clissold, S.: Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the “5E” study. Expert Rev. Pharmacoecon. Outcomes Res. 11, 205–213 (2011)
34. McCrone, P., Heslin, M., Knapp, M., Bull, P., Thompson, A.: Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics. 26, 847–860 (2008)
35. Buhse, M.: Assessment of caregiver burden in families of persons with multiple sclerosis. J. Neurosci. Nurs. 40, 25–31 (2008)
36. Postma, T.J., Oenema, D., Terpstra, S., Bouma, J., Kuipers-Upmeijer, H., Staal, M.J., Middel, B.J.: Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system. Pharmacoeconomics. 15, 395–404 (1999)
37. German Society for Multiple Sclerosis. Epidemiology of MS in Germany. Available at http://www.dmsg.de/multiple-sklerose-infos/index.php?w3pid=ms#Häufigkeit. Accessed on 10.10.2011
38. Farrar, J.T., Troxel, A.B., Stott, C., Duncombe, P., Jensen, M.P.: Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther. 30, 974–985 (2008)
39. Flachenecker, P., Meissner, H.: Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessment. Mult. Scler. 14, 274–277 (2008)
40. Nicholl, L., Hobart, J., Dunwoody, L., Cramp, F., Lowe-Strong, A.: Measuring disability in multiple sclerosis: is the Community Dependency Index an improvement on the Barthel Index? Mult. Scler. 10, 447–450 (2004)
41. Kurtzke, J.F.: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444–1452 (1983)
42. Group, EuroQol: EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16, 199–208 (1990)
43. Parkin, D., Rice, N., Jacoby, A., Doughty, J.: Use of a visual analogue scale in a daily patient diary: modelling cross-sectional time-series data on health-related quality of life. Soc. Sci. Med. 59, 351–360 (2004)
44. Vickrey, G., Hays, R.D., Harooni, F., Myers, L.W., Ellison, G.W.: A health-related quality of life measure for multiple sclerosis. Qual. Life Res. 4, 187–202 (1995)
45. Sosnoff, J.J., Shin, S., Motl, R.W.: Multiple sclerosis and postural control: the role of spasticity. Arch. Phys. Med. Rehabil. 91, 93–99 (2010)
46. Chang, C.H., Cella, D., Fernández, O., Luque, G., de Castro, P., de Andrés, C., Casanova, B., Hernández, M.A., Prieto, J.M., Fernández, V.E., de Ramón, E.: Grupo Español de Calidad de Vida en Esclerosis Múltiple. Quality of life in multiple sclerosis patients in Spain. Mult. Scler. 8, 527–531 (2002)
47. Morales-Gonzáles, J.M., Benito-León, J., Rivera-Navarro, J., Mitchell, A.J.: GEDMA Study Group. A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA study. Mult. Scler. 10, 47–54 (2004)
48. Olgiati, R., Burgunder, J.M., Mumenthaler, M.: Increased energy cost of walking in multiple sclerosis: effect of spasticity, ataxia, and weakness. Arch. Phys. Med. Rehabil. 69, 846–849 (1988)
49. Rothwell, P.M., McDowell, Z., Wong, C.K., Dorman, P.J.: Doctors and patients don’t agree: cross sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosis. BMJ 314, 1580–1583 (1997)
50. Brar, S.P., Smith, M.B., Nelson, L.M., Franklin, G.M., Cobble, N.D.: Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch. Phys. Med. Rehabil. 72, 186–189 (1991)
51. Shakespeare, D.T., Boggild, M., Young, C.: Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. 4, CD001332 (2001)
52. Bensmail, D., Ward, A.B., Wissel, J., Motta, F., Saltuari, L., Lissens, J., Cros, S., Beresniak, A.: Cost-effectiveness modelling of intrathecal baclofen therapy versus other interventions for disabling spasticity. Neurorehabil. Neural. Repair. 23, 546–552 (2009)
53. Nicolson, P., Anderson, P.: The psychosocial impact of spasticity-related problems for people with multiple sclerosis: a focus group study. J. Health Psychol. 6, 551–567 (2001)
54. Sosnoff, J.J., Gappmaier, E., Frame, A., Motl, R.W.: Influence of spasticity on mobility and balance in persons with multiple sclerosis. J. Neurol. Phys. Ther 35, 129–132 (2011)
55. Miller, A., Dishon, S.: Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status. Qual. Life Res. 15, 259–271 (2006)
56. Busche, K.D., Fisk, J.D., Murray, T.J., Metz, L.M.: Short term predictors of unemployment in multiple sclerosis patients. Can. J. Neurol. Sci. 30, 137–142 (2003)
57. Patti, F., Pozzilli, C., Montanari, E., Pappalardo, A., Piazza, L., Levi, A., Onesti, E., Pesci, I.: Italian study group on quality of life in MS. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Mult. Scler. 13, 783–791 (2007)
58. Pandyan, A.D., Johnson, G.R., Price, C.I., Curless, R.H., Barnes, M.P., Rodgers, H.: A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin. Rehabil. 13, 373–383 (1999)
59. Reese, J.P., John, A., Wienemann, G., Wellek, A., Sommer, N., Tackenberg, B., Balzer-Geldsetzer, M., Dodel, R.: Economic burden in a german cohort of patients with multiple sclerosis. Eur. Neurol. 66, 311–321 (2011)
60. Taylor, B., McDonald, E., Fantino, B., Sedal, L., MacDonnell, R., Pittas, F., Groom, T., Beresniak, A.: The cost of multiple sclerosis in Australia. J. Clin. Neurosci. 14, 532–539 (2007)
61. Grudzinski, A.N., Hakim, Z., Cox, R., Bootman, J.L.: The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. Pharmaeconomics 15, 229–240 (1999)
62. The Canadian Burden of Illness Study Group: Burden of illness of multiple sclerosis: Part I: Cost of illness. Can. J. Neurol. Sci. 25, 23–30 (1998)
63. Inman, R.P.: Disability indices, the economic costs of illness, and social insurance: the case of multiple sclerosis. Acta Neurol. Scand. 101, 46–55 (1984)
64. Jennum, P., Wanscher, B., Frederiksen, J., Kjellberg, J.: The socioeconomic consequences of multiple sclerosis: a controlled national study. Eur. Neuropsychopharmacol. 22, 36–43 (2012)
65. Olesen, J., Gustavsson, A., Svensson, M., Wittchen, H.U., Jönsson, B.: CDBE2010 study group; European Brain Council. The economic cost of brain disorders in Europe. Eur. J. Neurol. 19, 155–162 (2012)
66. Asche, C.V., Singer, M.S., Jhaveri, M., Chung, H., Miller, A.: All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J. Manag. Care Pharm. 16, 703–712 (2010)
67. Kobelt, G., Berg, J., Lindgren, P., Elias, W.G., Flachenecker, P., Freidel, M., König, N., Limmroth, V., Straube, E.: Costs and quality of life of multiple sclerosis in Germany. Eur. J. Health Econ. 7(Suppl 2), 34–44 (2006)
68. Whetten-Goldstein, K., Sloan, F.A., Goldstein, L.B., Kulas, E.D.: A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult. Scler. 4, 419–425 (1998)
69. Asche, C.V., Ho, E., Chan, B., Coyte, P.C.: Economic consequences of multiple sclerosis for Canadians. Acta Neurol. Scand. 95, 268–274 (1997)
70. Fleming, S.T.: Multiple sclerosis as a comorbidity: a study of resource utilization and outcomes of care. Clin. Perform. Qual. Health Care. 3, 23–30 (1995)
71. McCabew, M.P., De Judicibus, M.: The effects of economic disadvantage on psychological well-being and quality of life among people with multiple sclerosis. J. Health Psychol. 10, 163–173 (2005)
72. Catanzaro, M., Weinert, C.: Economic status of families living with multiple sclerosis. Int. J. Rehabil. Res. 15, 209–218 (1992)
73. Wundes, A., Brown, T., Bienen, E.J., Coleman, C.I.: Contribution of intangible costs to the economic burden of multiple sclerosis. J. Med. Econ. 13, 626–632 (2010)
74. Marrie, R.A., Horwitz, R., Cutter, G., Tyry, T.: Cumulative impact of comorbidity on quality of life in MS. Acta Neurol. Scand. 125, 180–186 (2012)
75. Jaracz, K., Pawlak, M., Górna, K., Kołcz, B., Wołoszyn, D., Kozubski, W.: Quality of life and social support in patients with multiple sclerosis. Neurol. Neurochir. Pol. 44, 358–365 (2010)
76. Rivera-Navarro, J., Benito-León, J., Oreja-Guevara, C., Pardo, J., Dib, W.B., Orts, E., Belló, M.: Caregiver Quality of Life in Multiple Sclerosis (CAREQOL-MS) Study Group. Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Mult. Scler. 15, 1347–1355 (2009)